hamburger-icon ABOUT US HISTORY 201020112012201320142015201620172018201920202021 Clinigen was formed through the merger of three successful companies: Keats Healthcare, Clinigen Healthcare and Clinigen. 2010 Peter George forms the Clinigen Group by bringing together Clinigen Pharma, Clinigen Healthcare and Keats Healthcare Clinigen acquires its first product, Foscavir and commences Global Access Programs supplying unlicensed medicines globally Employees: 32 2011 Clinigen recognised as the fastest-growing private company in the UK by the Sunday Times Virgin Fast Track 100 Employees: 48 2012 Clinigen moves warehousing into brand new Operations Centre Clinigen lists on the Alternative Investment Market (AIM) of the London Stock Exchange – the first UK healthcare company to list in London in five years Employees: 72 2013 Clinigen marks its first year as a public company by winning Best Newcomer at the London Stock Exchange AIM Awards Clinigen wins IPO of the Year at the 2013 M&A Awards Clinigen SP acquires its second product, Cardioxane Employees: 101 2014 Clinigen opens new, extended headquarters in Burton-on-Trent, UK Clinigen acquires its third product, Savene Clinigen acquires its fourth product, Ethyol Peter George wins Chief Executive of the Year at 2014 European Mediscience Awards Clinigen launches its new web portal, Cliniport, which allows healthcare professionals to order products directly via the internet Employees: 116 2015 Clinigen acquires Idis in April 2015 to become the global leader in providing ethical compliant access to unlicensed medicines Clinigen acquires Link Healthcare in October 2015 to expand its ability to provide access to medicines for patients in the Africa, Asia and Australia regions Clinigen awarded the ServiceMark accreditation by The Institute of Customer Service, in recognition of the Group’s commitment to, and achievement in, customer services Employees: 450 2016 Launch of Japanese business, Clinigen KK, with Foscavir as its first product Clinigen acquires its fifth product, Totect US, completing the global dexrazoxane portfolio Clinigen continues Foscavir development with purchase of a new bag presentation Clinigen launches Ethyol in the US in partnership with Cumberland Pharma Shaun Chilton replaces Peter George as Chief Executive Officer of Clinigen Group plc Employees: 530 2017 Clinigen receives investors in people silver award Clinigen receives EC approval for updates to Cardioxane product information Clinigen launched Totect in the US in partnership with Cumberland Pharma Clinigen acquires IMMC, Japan’s largest supplier of unlicensed medicines Clinigen acquires Quantum Pharma plc in November 2017 extending its Unlicensed Medicines capability and accelerating its unlicensed to licensed global strategy Employees: 849 2018 Clinigen signs extended partnership agreement with Bristol-Myers Squibb to supply its portfolio of products in South Africa Clinigen acquires its sixth product, Proleukin (global rights outside the US) Clinigen acquires its seventh product, Imukin (global rights outside the US, Canada and Japan) Clinigen acquires CSM a specialist provider of packaging, labelling, warehousing and distribution services with infrastructure in the US, Belgium and Germany Clinigen acquires iQone, a Swiss-based specialty pharmaceutical business providing EU medical scientific liaison (MSL) capability Employees: 1,182 2019 Clinigen acquires the US rights to Proleukin Clinigen Direct is a globally available service which helps clinicians, pharmacists and pharmacy technicians source hard to find medicines by connecting them with our specialist customer services team, either online or by phone (and even fax). 2020 Clinigen signs exclusive global licensing and distribution agreement to commercialise Erwinase Clinigen and GC Pharma collaboratively submit New Drug Application for Hunterase (Idursulfase-beta) ICV in Japan Clinigen expands footprint in Southeast Asia with opening of new Malaysia office 2021 Launched Hunterase in Japan and begin roll-out of Erwinase in licenced and unlicenced markets. COVID-19 headwinds impact demand for Proleukin and On-Demand. Divestment of UK Specials and Aseptics business As announced in the half year results, from 1 January 2021, the Group structure was simplified, moving from three divisions to two: Services and Products. This change better reflects the alignment of the Group’s activities to its end customers: pharmaceutical clients and healthcare professionals OUR GLOBAL OFFICES United Kingdom Europe Asia, Pacific and Japan South Africa United States SITE TOOLS Stay In Touch AE Reporting Medical enquiries Terms of use Cookies Privacy policy Privacy Statement for Pharmacovigilance Data UK Gender Pay Gap Report Modern Slavery Statement Access Online Sitemap Consumer Information Obligations Clinigen Terms And Conditions Of Business (Sales) Clinigen Terms And Conditions Of Business (Purchases) Cookie settings FIND A MEDICINE Online services for healthcare professionals Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Clinigen Products Twitter Linkedin © Copyright 2021 Clinigen Group plc. By Emperor OUR USE OF COOKIES We use cookies to improve your experience. By clicking accept, we will set recommended analytics cookies. AcceptRejectSettings